{
    "organizations": [],
    "uuid": "57c75d7a06d1bd73f374f7694e3cb70f0ecc0641",
    "author": "",
    "url": "https://www.reuters.com/article/brief-beigene-announces-approval-of-revl/brief-beigene-announces-approval-of-revlimid-in-china-idUSFWN1QH1GG",
    "ord_in_thread": 0,
    "title": "BRIEF-Beigene Announces Approval Of Revlimid In China",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Beigene Ltd:\n* BEIGENE ANNOUNCES APPROVAL OF REVLIMID® FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA\n* BEIGENE LTD - ‍REVLIMID HAS BEEN APPROVED BY CHINA FOOD AND DRUG ADMINISTRATION FOR TREATMENT OF MULTIPLE MYELOMA​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-28T01:10:00.000+02:00",
    "crawled": "2018-02-28T01:25:19.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "beigene",
        "ltd",
        "beigene",
        "announces",
        "approval",
        "newly",
        "diagnosed",
        "multiple",
        "myeloma",
        "china",
        "beigene",
        "ltd",
        "approved",
        "china",
        "food",
        "drug",
        "administration",
        "treatment",
        "multiple",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}